Medical Oncology

Richard Francis Riedel, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept Of Medicine, 25179 Morris Bldg, Durham, NC 27710
Phone (919) 681-8031
Email address richard.riedel@duke.edu

Novel therapies for soft tissue and bone sarcomas

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2007
  • Fellow in Hematology-Oncology, Medicine, Duke University, 2003 - 2004
  • Resident in Medicine, Medicine, Duke University, 2000 - 2003
  • M.D., Thomas Jefferson University, 2000

Grants

Publications

Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.

PMID
29572245
Full Text

Wisdom, AJ, Mowery, YM, Riedel, RF, and Kirsch, DG. "Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma." Cancer (May 3, 2018). (Review)

PMID
29723407
Full Text

von Mehren, M, Randall, RL, Benjamin, RS, Boles, S, Bui, MM, Ganjoo, KN, George, S, Gonzalez, RJ, Heslin, MJ, Kane, JM, Keedy, V, Kim, E, Koon, H, Mayerson, J, McCarter, M, McGarry, SV, Meyer, C, Morris, ZS, O'Donnell, RJ, Pappo, AS, Paz, IB, Petersen, IA, Pfeifer, JD, Riedel, RF, Ruo, B, Schuetze, S, Tap, WD, Wayne, JD, Bergman, MA, and Scavone, JL. "Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network 16, no. 5 (May 2018): 536-563.

Full Text

Plenker, D, Bertrand, M, de Langen, AJ, Riedel, R, Lorenz, C, Scheel, AH, Müller, J, Brägelmann, J, Daßler-Plenker, J, Kobe, C, Persigehl, T, Kluge, A, Wurdinger, T, Schellen, P, Hartmann, G, Zacherle, T, Menon, R, Thunnissen, E, Büttner, R, Griesinger, F, Wolf, J, Heukamp, L, Sos, ML, and Heuckmann, JM. "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients." Clinical Cancer Research 24, no. 6 (March 15, 2018): 1337-1343.

Full Text

Tawbi, HA, Burgess, M, Bolejack, V, Van Tine, BA, Schuetze, SM, Hu, J, D'Angelo, S, Attia, S, Riedel, RF, Priebat, DA, Movva, S, Davis, LE, Okuno, SH, Reed, DR, Crowley, J, Butterfield, LH, Salazar, R, Rodriguez-Canales, J, Lazar, AJ, Wistuba, II, Baker, LH, Maki, RG, Reinke, D, and Patel, S. "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial." The Lancet. Oncology 18, no. 11 (November 2017): 1493-1501.

PMID
28988646
Full Text

Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca, , and Cancer Genome Atlas Research Network, . "Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas." Cell 171, no. 4 (November 2017): 950-965.e28.

PMID
29100075
Full Text

Riedel, R, and Wolf, J. "[Personalized therapy of lung cancer - current standard and future challenges]." Deutsche medizinische Wochenschrift (1946) 142, no. 22 (November 2017): 1660-1668.

PMID
29078211
Full Text

Riedel, RF, Slusser, K, Power, S, Jones, CA, LeBlanc, TW, Kamal, AH, Desai, D, Allen, D, Yu, Y, Wolf, S, and Galanos, AN. "Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service." Journal of Oncology Practice 13, no. 9 (September 2017): e738-e748.

PMID
28796559
Full Text

Chawla, S, Van Tine, BA, Pollack, S, Ganjoo, K, Elias, A, Riedel, RF, Attia, S, Choy, E, Okuno, S, Agulnik, M, von Mehren, M, Livingston, M, Keedy, V, Verschraegen, C, Philip, T, Bohac, C, Lu, H, Chen, M, and Maki, R. "A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival." September 2017.

Scholars@Duke

Tap, WD, Papai, Z, Van Tine, BA, Attia, S, Ganjoo, KN, Jones, RL, Schuetze, S, Reed, D, Chawla, SP, Riedel, RF, Krarup-Hansen, A, Toulmonde, M, Ray-Coquard, I, Hohenberger, P, Grignani, G, Cranmer, LD, Okuno, S, Agulnik, M, Read, W, Ryan, CW, Alcindor, T, Del Muro, XFG, Budd, GT, Tawbi, H, Pearce, T, Kroll, S, Reinke, DK, and Schöffski, P. "Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial." The Lancet. Oncology 18, no. 8 (August 2017): 1089-1103.

PMID
28651927
Full Text

Pages